Altimmune, Inc.
ALT
$2.91
-$0.02-0.68%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 420.00% | 0.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 420.00% | 0.00% | 0.00% | 0.00% |
| Cost of Revenue | 2.31% | -6.94% | -24.46% | -18.53% | -26.34% |
| Gross Profit | -2.34% | 7.04% | 24.46% | 18.53% | 26.35% |
| SG&A Expenses | 34.36% | 106.48% | 18.82% | 1.72% | 12.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.11% | 16.28% | -15.78% | -14.29% | -18.58% |
| Operating Income | -11.13% | -16.19% | 15.78% | 14.29% | 18.58% |
| Income Before Tax | -11.39% | -18.02% | 16.77% | 10.12% | 16.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.26% | -18.02% | 16.77% | 10.12% | 19.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.26% | -18.02% | 16.77% | 10.12% | 19.75% |
| EBIT | -11.13% | -16.19% | 15.78% | 14.29% | 18.58% |
| EBITDA | -11.18% | -16.24% | 15.76% | 14.21% | 18.36% |
| EPS Basic | 30.03% | 16.42% | 33.85% | 21.76% | 24.79% |
| Normalized Basic EPS | 32.40% | 16.43% | 33.85% | 21.74% | 22.16% |
| EPS Diluted | 30.03% | 16.42% | 33.85% | 21.76% | 24.79% |
| Normalized Diluted EPS | 32.40% | 16.43% | 33.85% | 21.74% | 22.16% |
| Average Basic Shares Outstanding | 64.75% | 41.19% | 25.79% | 14.88% | 6.70% |
| Average Diluted Shares Outstanding | 64.75% | 41.19% | 25.79% | 14.88% | 6.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |